

Anti-SLAMF7/CS1 Antibody (Elotuzumab)

Introduction

Elotuzumab is aSLAMF7 Elotuzumab is a monoclonal antibody that targets a receptor for leukemia. When given as a single active molecule in relapsed or refractory multiple myeloma (RRMM), elotuzumab has no significant anti-myeloma activity. Elotuzumab may improve responses and outcomes when used in combination with other anti-myeloma active molecules.

Product parameters

Alternative Names	Empliciti, HuLuc63, PDL063
Target Accession	Q9NQ25
Target	SLAMF7 / CS1
CAS number	915296-00-3
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

